Sanofi Pasteur Reports Positive Results For Panenza, Humenza Clinical Trials

Sanofi Pasteur, the vaccines division of the sanofi-aventis group, has revealed that a single dose of influenza A (H1N1) 2009 monovalent vaccines, Panenza or Humenza, administered to children and adults induces a robust immune response. The findings were obtained from clinical trials conducted in Europe.

The company said that one dose of Panenza or Humenza Influenza A (H1N1) 2009 monovalent vaccine induces a robust antibody response, that is considered protective in 93% or more of adults 18 to 59 years old and in 83% or more of adults 60 years of age and older. In children 3 years of age through 17 years of age, 94% or more of study participants achieved seroprotective antibody response.

Wayne Pisano, president and CEO of Sanofi Pasteur, said: “These significant clinical data concerning Sanofi Pasteur’s pandemic influenza vaccines will help build public confidence in the vaccine and will support efforts by health authorities to face the challenge posed by pandemic influenza.

“Humenza and Panenza vaccines are effective answers to different public health needs. Humenza, a lowdose adjuvanted vaccine, has the potential to expand pandemic production capacities and to increase the number of doses of vaccine available, making it possible to immunize more people; Panenza, standarddose non-adjuvanted vaccine, may be considered by European authorities as the vaccine of choice to protect specific at-risk populations.”

Sanofi-aventis is a global pharmaceutical company that discovers, develops and distributes therapeutic solutions.